To Empower the Body

To Prevent, Treat and Resist Diseases

We address issues limiting the development and use of current therapeutics for clinically unmet needs in Oncology, Pulmonary, Neurodegenerative and Infectious diseases. Our platform is based on novel insights into the relational synergy among the active molecules, pleiotropic modes of action and homeostatic mechanisms that maintain health as well as the imbalances that cause diseases. Using this approach, we design therapeutics to work with the body’s own defenses to create safe, effective and affordable therapies

While our team has a breadth of experience – drug development, clinical, regulatory affairs and commercialization of products – the singular element that drives the team is a sense of fierce urgency to develop and deliver therapeutics to patients who are not served by the currently available options.

Parag G. Mehta, PhD, Co-founder and CEO is a serial entrepreneur with a track record of commercializing novel chemistry based innovations. He has strong background in biotechnology, organic, macromolecular and biochemistry and material science. His experience encompasses product R&D, global business development, manufacturing and capitalization of companies through public and private financing.  He received his PhD in Chemistry from Rensselaer Polytechnic Institute, Troy, NY and MSc in Chemistry from Indian Institute of Technology, Mumbai, India.

Sharmila Mudgal, MD, MPH, Co-founder and Chief Medical Officer is a Board Certified physician with a background in clinical medicine and public health. She got her MBBS from the University of Mumbai, India. She did her residency in Otolaryngology in India and Liverpool, UK and a residency/fellowship in Occupational and Environmental Medicine at the Harvard School of Public Health. She received her Masters in Public Health (Epidemiology and Biostatistics) from the Boston University School of Public Health. She has held research and academic positions both at Harvard Medical School and Harvard School of Public Health. She served as a Consultant Physician on Clinical studies. Her interest in Public Health and Prevention led to the exploration for safer alternatives to currently used medications to treat inflammation and other chronic diseases. In addition to being the Chief Medical Officer, she also leads the Regulatory Affairs Division at Aveta Biomics.
Luis Z Avila, PhD, Vice President, Drug Discovery & Development, brings to Aveta Biomics more than 20 years of industrial experience spanning early startup (Focal, Inc) through biotech (Genzyme) and most recently as Distinguished Scientific Fellow at a multinational pharmaceutical company (Sanofi). He has successfully guided several product concepts through various phases of discovery, optimization, product development and CMC for clinical evaluation and/or product launch (either internally and with external company collaborators). He obtained his PhD in Bioorganic Chemistry from Stanford University and was a Postdoctoral Fellow at Harvard University (Department of Chemistry and Chemical Biology). He holds more than twenty issued US patents and coauthored more than twenty scientific articles and book chapters on topics including bioorganic chemistry, biomaterials, drug delivery, bioconjugation and biologic+synthetic hybrid products.
S. P. Kothari, Member of the Board of Directors, is Gordon Y Billard Professor of Accounting and Finance at the Sloan School of Management, Massachusetts Institute of Technology. Previously, Dr. Kothari served as global head of equity research for Barclays Global Investors (BGI), where he led an international research team supporting BGI’s actively managed equity portfolio (>$100 billion in assets) strategies, from 2008-09. He consults with leading US and international banks and asset management companies, Australian television broadcast corporations, US steel companies, E&Y, KPMG, Price Waterhouse Coopers, and the U.S. DOJ. Dr. Kothari served on the Board of Visions from 1998-2004 and is currently on the Boards of BSE (Bombay Stock Exchange) and Trillium Asset Management. He has written numerous opinion-page editorials in The Wall Street Journal, The Economic Times, The Hindu Business Line, etc.

Bharat Aggarwal, PhD, Scientific Advisor, Director of Inflammation Research Institute in San Diego, CA and a just retired Chaired professor and chief of the Cytokine Research at M.D. Anderson Cancer Center, Univ. of Texas is world’s foremost researcher in areas of inflammation and is well-known for his ground-breaking work on use of natural products to combat many diseases.  Earlier at Genentech his team characterized TNF-alpha and TNF-beta, key cytokines involved in cancer. He has made seminal contributions in inflammation biology, role of cytokines in tumor cell growth and mechanism of tumor cell resistance. He has authored more than 500 original articles in peer-reviewed journals, edited 12 books, is co-inventor of 33 patents, and has Scholar h-index of 157 with 89,500 citations.

Eugene I. Shakhnovich, PhD, Scientific Advisor is a Professor of Chemistry and Chemical Biology at Harvard University.  He is one of the leading researchers in the areas of protein folding and has carried out crucial work tying the physical chemistry of protein with the evolutionary biology. His laboratory has made fundamental contributions to understanding of the mechanisms of drug resistance by studying the mutational fitness of an organismal evolution using the biophysical principles. He is the author of more than 200 publications, serves on the editorial boards of several major journals and is a recipient of several awards and fellowships. Prof. Shakhnovich is also an entrepreneur who co-founded Vitae Pharmaceuticals (NASDAQ:VTAE) which was recently acquired by Allergan for $639 million.
Daniel L. Hartl, PhD, Scientific Advisor is Higgins Professor of Biology and former Chair of the Department of Organismic and Evolutionary Biology at Harvard University. His laboratory studies genetics, genomics and molecular evolution. His seminal contributions to experimental evolutionary genetics have far-reaching impact on understanding the development of resistance to drugs in human diseases. An elected member of the National Academy of Sciences, USA, the American Academy of Arts and Sciences, and the National Academy of Sciences of India, Prof. Hartl has been honored with the Samuel Weiner Outstanding Scholar Award and the Medal of the Stazione Zoologica Anton Dohrn. He is a Past President of the Genetics Society of America and the Society for Molecular Biology and Evolution and has served on the National Institutes of Health Genetics Study Section, Genetic Basis of Disease Review Committee, and on the Editorial Boards of Genetics, Annual Review of Genetics and, Molecular Biology and Evolution. He has authored or coauthored more than 400 scientific articles and 20 books including Genetics: Analysis of Genes and Genomes, Essential Genetics: A Genomics Perspective, Principles of Population Genetics and Primer of Population Genetics.

David C. Christiani, MD. MPH, MS, Scientific Advisor  is a Professor of Medicine at Harvard Medical School, Physician, Pulmonary and Critical Care Unit of MGH, and the Elkan Blout Professor of Environmental Genetics at the Harvard School of Public Health. He has conducted clinical trials in lung disease, and has chaired or served on several DSMB’s for ongoing trials in lung disease and cancer.  He has been a leader in studying biomarkers of risk and outcome in cancer and in acute and chronic lung injury. He has authored or co-authored over 600 publications.  In 2012, he was appointed by President Obama to serve on the National Cancer Advisory Board.